Answers are grounded in this paper and cite their sources.
Covalent labeling of nucleophilic amino acids is a useful strategy for liganding ‘difficult-to-drug’ protein targets. Targeting cysteine has been highly successful because of its high nucleophilicity. Covalent ligands that modify lysine residues can provide broader proteome coverage for covalent inhibition. Sulfur(VI) fluorides are lysine-reactive electrophiles with highly tunable intrinsic reactivities, making them well-suited as covalent reactivity handles. Association of the NUP98::KDM5A fusion oncoprotein with chromatin via the PHD3 domain of KDM5A is a key driver of acute myeloid leukemia. Despite its therapeutic relevance, there are currently no high-quality chemical probes for this domain, owing to the solvent-exposed and extended H3K4me3-binding region. Here, we report the development of lysine-reactive cyclic peptides targeting KDM5A PHD3 via a sulfur(VI) fluoride reactivity-tuning approach. Through sulfur(VI) fluoride electrophile SAR, we identified a p-substituted aryl fluorosulfate that balanced PHD3 labeling, hydrolytic stability, and covalent adduct persistence. Using the optimized aryl fluorosulfate electrophile, we report covalent ligands designed to target KDM5A PHD3 and demonstrate their engagement with the NUP98::KDM5A fusion oncoprotein in cell lysate. Proteomic analysis also identified the H3K4me3 reader domain PHF23 as a target of the covalent cyclic peptides, indicating that these compounds may provide a starting point for developing ligands for the PHF23 PHD domain. This study highlights sulfur(VI) fluoride reactivity tuning as an effective approach for engaging ‘difficult-to-drug’ proteins.
No takes yet. Share an insight, caveat, or question.
McArdle et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: